Advertisement

Molecular Diagnostics as Basis of Personalized Medicine

  • Kewal K. Jain
Chapter

Abstract

Molecular diagnostics, the use of diagnostic testing to understand the molecular mechanisms of an individual patient’s disease, will be pivotal in the delivery of safe and effective therapy for many diseases in the future. Role of molecular diagnostics in personalized medicine covers the following aspects: Early detection and selection of appropriate treatment determined to be safe and effective on the basis of molecular diagnostics Integration of molecular diagnostics with therapeutics Monitoring therapy as well as determining prognosis

Keywords

Positron Emission Tomography Single Nucleotide Polymorphism Personalized Medicine Molecular Diagnostics Single Nucleotide Polymorphism Genotyping 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Jain KK (2005) Personalised medicine for cancer – from drug development into clinical practice. Exp Opin Pharmacother 6:1463–1476CrossRefGoogle Scholar
  2. Jain KK (2007) Applications of nanobiotechnology in clinical diagnostics. Clin Chem 53:2002–2009CrossRefPubMedGoogle Scholar
  3. Jain KK (2008) A handbook of nanomedicine. Springer/Human Press, Tatowa, NJ.Google Scholar
  4. Jain KK (2009a) Molecular diagnostics: technologies, markets and companies. Jain PharmaBiotech, Basel, Switzerland.Google Scholar
  5. Jain KK (2009b) DNA sequencing: technologies, markets and companies. Jain PharmaBiotech, Basel, Switzerland.Google Scholar
  6. Jain KK (2009c) Biochips/microarrays: technologies, markets and companies. Jain PharmaBiotech, Basel, Switzerland.Google Scholar
  7. Jain KK (2009d) Nanobiotechnology: applications, markets and companies. Jain PharmaBiotech, Basel, Switzerland.Google Scholar
  8. Jain KK (2009e) Proteomics: technologies, markets and companies. Jain PharmaBiotech, Basel, Switzerland.Google Scholar
  9. Jain KK (2009n) Cytogenetics: technologies, markets and companies. Jain PharmaBiotech, Basel, Switzerland.Google Scholar
  10. Lin M, Aquilante C, Johnson JA, Wu R (2005) Sequencing drug response with HapMap. Pharma-cogenomics J 5:149–156CrossRefPubMedGoogle Scholar
  11. Manolio TA, Brooks LD, Collins FS (2008) A HapMap harvest of insights into the genetics of common disease. J Clin Invest 118:1590–1605CrossRefPubMedGoogle Scholar
  12. Valet G (2005) Cytomics, the human cytome project and systems biology: top-down reso-lution of the molecular biocomplexity of organisms by single cell analysis. Cell Prolif 38:171–174CrossRefPubMedGoogle Scholar
  13. Zhang J, Lang HP, Huber F et al (2006) Rapid and label-free nanomechanical detection of biomarker transcripts in human RNA. Nat Nanotechnol 1:214–220CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Jain PharmaBiotechBaselSwitzerland

Personalised recommendations